- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
LeWitt PA et al. (2008) Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial
(6002-US-005). Ann Neurol 63: 295–302
The efficacy of levodopa therapy for Parkinson's disease (PD) declines with time, and some patients experience breakthrough motor symptoms as doses wear off. These motor fluctuations are
caused by an overactive striatopallidal output pathway, so they could potentially be alleviated by blockade of A2A adenosine receptors on striatopallidal neurons. To test this theory, LeWitt
and colleagues investigated the effects of istradefylline, a selective adenosine A2A receptor antagonist, in patients with PD who were receiving levodopa therapy.
Anyone you share the following link with will be able to read this content:
